CN109415335B - 罗替戈汀山嵛酸酯及其制备方法和用途 - Google Patents

罗替戈汀山嵛酸酯及其制备方法和用途 Download PDF

Info

Publication number
CN109415335B
CN109415335B CN201680087177.7A CN201680087177A CN109415335B CN 109415335 B CN109415335 B CN 109415335B CN 201680087177 A CN201680087177 A CN 201680087177A CN 109415335 B CN109415335 B CN 109415335B
Authority
CN
China
Prior art keywords
rotigotine
behenate
rotigotine behenate
solvent
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680087177.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN109415335A (zh
Inventor
杨米娜
姜永涛
孟莹
王涛
徐钱钱
邵馨
沙春洁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Qianhu Pharmaceutical Technology Co ltd
Original Assignee
Shandong Luye Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Luye Pharmaceutical Co Ltd filed Critical Shandong Luye Pharmaceutical Co Ltd
Publication of CN109415335A publication Critical patent/CN109415335A/zh
Application granted granted Critical
Publication of CN109415335B publication Critical patent/CN109415335B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
    • C07D333/10—Thiophene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
CN201680087177.7A 2016-07-21 2016-07-21 罗替戈汀山嵛酸酯及其制备方法和用途 Active CN109415335B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/090803 WO2018014277A1 (zh) 2016-07-21 2016-07-21 罗替戈汀山嵛酸酯及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN109415335A CN109415335A (zh) 2019-03-01
CN109415335B true CN109415335B (zh) 2020-06-05

Family

ID=60992805

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680087177.7A Active CN109415335B (zh) 2016-07-21 2016-07-21 罗替戈汀山嵛酸酯及其制备方法和用途

Country Status (15)

Country Link
US (2) US10669249B2 (https=)
EP (1) EP3489227B1 (https=)
JP (1) JP6751208B2 (https=)
KR (1) KR20190031314A (https=)
CN (1) CN109415335B (https=)
AU (1) AU2016415408B2 (https=)
BR (1) BR112019001035A2 (https=)
CA (1) CA3030043C (https=)
ES (1) ES2855976T3 (https=)
MY (1) MY195897A (https=)
PH (1) PH12018550212A1 (https=)
PL (1) PL3489227T3 (https=)
RU (1) RU2717542C9 (https=)
SG (1) SG11201811543XA (https=)
WO (1) WO2018014277A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2717542C9 (ru) * 2016-07-21 2020-08-12 Шаньдун Луе Фармасьютикал Ко., Лтд. Ротиготина бегенат, его способ получения и применение
CN108341798B (zh) * 2017-01-23 2021-05-25 沈阳药科大学 罗替戈汀衍生物及其制备和应用
CN114423746A (zh) * 2019-09-30 2022-04-29 山东绿叶制药有限公司 化合物及其制备方法和用途
JP7621009B2 (ja) * 2020-10-27 2025-01-24 ▲広▼州市恒▲諾▼康医▲薬▼科技有限公司 テトラヒドロナフタレン系化合物、その医薬組成物及びその使用
WO2024208226A1 (zh) * 2023-04-04 2024-10-10 广州市恒诺康医药科技有限公司 四氢萘类化合物、其药物组合物及其用途
CN119504742B (zh) * 2024-11-18 2025-10-28 陕西师范大学 一种娃儿藤碱和安托芬的全合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013168033A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2016014242A1 (en) * 2014-07-21 2016-01-28 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239196T3 (es) * 2002-12-02 2005-09-16 Schwarz Pharma Ag Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson.
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
KR101481643B1 (ko) 2010-11-25 2015-01-12 산동 루예 파마슈티칼 컴파니 리미티드 로티고틴, 이의 유도체 또는 로티고틴 또는 이의 유도체의 약제학적으로 허용가능한 염의 조성물
US9956201B2 (en) * 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
RU2717542C9 (ru) * 2016-07-21 2020-08-12 Шаньдун Луе Фармасьютикал Ко., Лтд. Ротиготина бегенат, его способ получения и применение

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013168033A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2016014242A1 (en) * 2014-07-21 2016-01-28 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods

Also Published As

Publication number Publication date
BR112019001035A2 (pt) 2019-04-30
PL3489227T3 (pl) 2021-05-04
JP2019523297A (ja) 2019-08-22
MY195897A (en) 2023-02-27
US20200255396A1 (en) 2020-08-13
RU2717542C1 (ru) 2020-03-24
PH12018550212A1 (en) 2019-10-28
AU2016415408B2 (en) 2019-04-11
EP3489227B1 (en) 2020-10-21
US10669249B2 (en) 2020-06-02
CN109415335A (zh) 2019-03-01
AU2016415408A1 (en) 2019-01-17
CA3030043C (en) 2021-01-19
JP6751208B2 (ja) 2020-09-02
SG11201811543XA (en) 2019-02-27
WO2018014277A1 (zh) 2018-01-25
US20190330177A1 (en) 2019-10-31
EP3489227A4 (en) 2020-01-22
ES2855976T3 (es) 2021-09-27
EP3489227A1 (en) 2019-05-29
US11111227B2 (en) 2021-09-07
RU2717542C9 (ru) 2020-08-12
CA3030043A1 (en) 2018-01-25
KR20190031314A (ko) 2019-03-25

Similar Documents

Publication Publication Date Title
CN109415335B (zh) 罗替戈汀山嵛酸酯及其制备方法和用途
JP2019523297A5 (https=)
US10273262B2 (en) Crystalline form A of obeticholic acid and preparation method thereof
CN118852041B (zh) 6-((5,6-二苯基-1,2,4-三嗪-3-基)(异丙基)氨基)-n-(甲基磺酰基)己酰胺晶型a及其用途和制备方法
WO2021233133A1 (zh) 用作ret激酶抑制剂的化合物及其应用
CN108947989B (zh) 氘代光学异构体及其医药用途
TWI745764B (zh) 一種鴉片類物質受體激動劑的結晶形式及製備方法
CN116768909B (zh) Vanin酶抑制剂的盐型、晶型及其制备方法和应用
WO2024188169A1 (zh) 别孕烷醇酮衍生物的盐型、多晶型及其制备方法和用途
CN106810593B (zh) 一种丹参酮类化合物17位酯化衍生物及其制备工艺和应用
HK40004499A (en) Rotigotine behenate, and manufacturing method and application thereof
HK40004499B (en) Rotigotine behenate, and manufacturing method and application thereof
CN109641934B (zh) 胆酸衍生物游离碱，晶型及其制备方法和应用
WO2013170738A1 (zh) 阿戈美拉汀酸根复合物及其制备方法和用途
CN104650109A (zh) 紫杉烷类化合物
JP6533794B2 (ja) タキサン化合物、その調製方法およびその使用
CN107540589A (zh) 一种艾尔骨化醇晶型、药物组合物及制备方法和应用
CN116410165B (zh) 一种淫羊藿素与尿素共晶
RU2847971C2 (ru) Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции
RU2779119C2 (ru) Соль агониста опиоидного рецептора (mor), кристаллическая форма i его фумаратной соли и способ их получения
WO2017031994A1 (zh) 曲沙他滨的合成及其晶型
EA050240B1 (ru) Полиморфы ингибитора ssao
WO2017076358A1 (zh) 咪唑基联苯基化合物盐的新晶型及其制备方法
CN102675402A (zh) 4，16β-二胺基甾体季铵盐衍生物及其制备方法和应用
CN121419965A (zh) 吡啶氮氧化合物的盐型、共晶及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40004499

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20240416

Address after: 5th Floor, Runjiang Headquarters International Building, No. 455 Yuhua East Road, High tech Zone, Shijiazhuang City, Hebei Province, 050000

Patentee after: Green Leaf Jiaao Pharmaceutical Shijiazhuang Co.,Ltd.

Country or region after: China

Address before: 264670 No. 15 Pioneering Road, Yantai High-tech Zone, Shandong Province

Patentee before: SHANDONG LUYE PHARMACEUTICAL Co.,Ltd.

Country or region before: China

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240626

Address after: Room 0112, 4th Floor, Building 24, No. 68 Beiqing Road, Haidian District, Beijing, 100094

Patentee after: Beijing Qianhu Pharmaceutical Technology Co.,Ltd.

Country or region after: China

Address before: 5th Floor, Runjiang Headquarters International Building, No. 455 Yuhua East Road, High tech Zone, Shijiazhuang City, Hebei Province, 050000

Patentee before: Green Leaf Jiaao Pharmaceutical Shijiazhuang Co.,Ltd.

Country or region before: China

TR01 Transfer of patent right